Apparently, balanced chromosomal rearrangements usually have no phenotypic consequences for the carrier. However, in some cases, they may be associated with an abnormal phenotype. We report herein the case of a 4-year-old boy presenting with clinically isolated supravalvular aortic stenosis (SVAS). No chromosomal imbalance was detected by array CGH. The karyotype showed a balanced paracentric chromosome 7 inversion. Breakpoint characterization using paired-end whole-genome sequencing (WGS) revealed an ELN gene disruption in intron 1, accounting for the phenotype. Family study showed that the inversion was inherited, with incomplete penetrance. To our knowledge, this is the first case of a disruption of the ELN gene characterized by WGS. It contributes to refine the genotype-phenotype correlation in ELN disruption. Although this disruption is a rare etiology of SVAS, it cannot be detected by the diagnostic tests usually performed, such as array CGH or sequencing methods (Sanger, panel, or exome sequencing). With the future perspective of WGS as a diagnostic tool, it will be important to include a structural variation analysis in order to detect balanced rearrangements and gene disruption.

Keywords:
Whole-genome sequencing, Elastin, ELN, Paracentric inversion, Supravalvular aortic stenosis
1.
Curran ME, Atkinson DL, Ewart AK, Morris CA, Leppert MF, Keating MT: The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis. Cell 73:159-168 (1993).
2.
Duba HC, Doll A, Neyer M, Erdel M, Mann C, et al: The elastin gene is disrupted in a family with a balanced translocation t(7;16)(q11.23;q13) associated with a variable expression of the Williams-Beuren syndrome. Eur J Hum Genet 10:351-361 (2002).
3.
Malčić I, Dilber D, Kniewald H, Lasan R, Begović D, Jelušić M: Supravalvular aortic stenosis and peripheral pulmonary stenosis in family with balanced translocation T(7;14) and break point within the elastin gene region. Paediatr Croat 52:77-81 (2008).
4.
Merla G, Brunetti-Pierri N, Piccolo P, Micale L, Loviglio MN: Supravalvular aortic stenosis: elastin arteriopathy. Circ Cardiovasc Genet 5:692-696 (2012).
5.
Metcalfe K, Rucka AK, Smoot L, Hofstadler G, Tuzler G, et al: Elastin: mutational spectrum in supravalvular aortic stenosis. Eur J Hum Genet 8:955-963 (2000).
6.
Ottaviani D, LeCain M, Sheer D: The role of microhomology in genomic structural variation. Trends Genet 30:85-94 (2014).
7.
Pober BR: Williams-Beuren syndrome. N Engl J Med 362:239-252 (2010).
8.
Poninska JK, Bilinska ZT, Franaszczyk M, Michalak E, Rydzanicz M, et al: Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations. J Transl Med 14:115 (2016).
9.
Schluth-Bolard C, Labalme A, Cordier MP, Till M, Nadeau G, et al: Breakpoint mapping by next generation sequencing reveals causative gene disruption in patients carrying apparently balanced chromosome rearrangements with intellectual deficiency and/or congenital malformations. J Med Genet 50:144-150 (2013).
10.
Seidelmann SB, Smith E, Subrahmanyan L, Dykas D, Abou Ziki MD, et al: Application of whole exome sequencing in the clinical diagnosis and management of inherited cardiovascular diseases in adults. Circ Cardiovasc Genet 10:e001573 (2017).
11.
von Dadelszen P, Chitayat D, Winsor EJ, Cohen H, MacDonald C, et al: De novo 46,XX,t(6;7)(q27;q11;23) associated with severe cardiovascular manifestations characteristic of supravalvular aortic stenosis and Williams syndrome. Am J Med Genet 90:270-275 (2000).
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.